$ERNA
Eterna Therapeutics Inc.

2023 Q4 Form 10-Q Financial Statement

#000114036123052742 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $17.00K $51.00K $0.00
YoY Change
Cost Of Revenue $66.00K $120.0K $0.00
YoY Change
Gross Profit -$49.00K -$69.00K $0.00
YoY Change
Gross Profit Margin -288.24% -135.29%
Selling, General & Admin $4.506M $3.980M $3.340M
YoY Change 62.09% 19.16% -21.56%
% of Gross Profit
Research & Development $1.210M $1.457M $4.963M
YoY Change -38.27% -70.64% 238.39%
% of Gross Profit
Depreciation & Amortization $24.00K $20.00K $40.00K
YoY Change 20.0% -50.0% 36.71%
% of Gross Profit
Operating Expenses $5.716M $5.436M $8.304M
YoY Change 20.59% -34.54% 466.19%
Operating Profit -$5.765M -$5.505M -$8.304M
YoY Change -33.71% -90.38%
Interest Expense -$476.0K -$110.0K -$20.00K
YoY Change 4660.0% 450.0% -1.04%
% of Operating Profit
Other Income/Expense, Net $84.00K -$94.00K $993.0K
YoY Change -72.0% -109.47% 258.39%
Pretax Income -$6.157M -$5.599M -$7.311M
YoY Change 38.36% -23.42% -91.5%
Income Tax -$4.000K -$8.000K $5.000K
% Of Pretax Income
Net Earnings -$6.161M -$5.600M -$7.300M
YoY Change 36.91% -23.29% -91.52%
Net Earnings / Revenue -36241.18% -10980.39%
Basic Earnings Per Share -$1.03 -$2.49
Diluted Earnings Per Share -$1.14 -$1.03 -$2.49
COMMON SHARES
Basic Shares Outstanding 5.410M 5.410M 58.83M
Diluted Shares Outstanding 5.410M 2.941M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.575M $4.550M $13.25M
YoY Change -33.84% -65.66% -45.66%
Cash & Equivalents $7.575M $4.551M $13.25M
Short-Term Investments
Other Short-Term Assets $1.599M $700.0K $1.670M
YoY Change 24.92% -58.08% 23.41%
Inventory
Prepaid Expenses
Receivables $425.0K $1.780M
Other Receivables $425.0K $1.776M $926.0K
Total Short-Term Assets $9.599M $7.031M $15.85M
YoY Change -29.84% -55.65% -38.46%
LONG-TERM ASSETS
Property, Plant & Equipment $493.0K $173.0K $231.0K
YoY Change 108.9% -25.11% -94.52%
Goodwill $2.000M $2.000M $2.000M
YoY Change 0.0% 0.0% -2.14%
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $68.00K
YoY Change -100.0% -100.0% -93.2%
Other Assets $120.0K $4.045M $819.0K
YoY Change -89.42% 393.89%
Total Long-Term Assets $39.53M $45.22M $5.074M
YoY Change 359.79% 791.15% -62.79%
TOTAL ASSETS
Total Short-Term Assets $9.599M $7.031M $15.85M
Total Long-Term Assets $39.53M $45.22M $5.074M
Total Assets $49.13M $52.25M $20.93M
YoY Change 120.53% 149.68% -46.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.067M $1.464M $1.150M
YoY Change -34.14% 27.3% 15.43%
Accrued Expenses $1.893M $5.019M $3.230M
YoY Change -47.79% 55.39% 51.75%
Deferred Revenue
YoY Change
Short-Term Debt $1.205M $1.640M $0.00
YoY Change -31.14%
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.573M $9.626M $7.467M
YoY Change -14.12% 28.91% 63.73%
LONG-TERM LIABILITIES
Long-Term Debt $6.773M $3.450M $10.00K
YoY Change 459.75% 34400.0%
Other Long-Term Liabilities $33.55M $35.61M $1.690M
YoY Change 35594.68% 2007.1% -92.25%
Total Long-Term Liabilities $40.33M $39.06M $1.690M
YoY Change 42800.0% 2211.24% -92.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.573M $9.626M $7.467M
Total Long-Term Liabilities $40.33M $39.06M $1.690M
Total Liabilities $46.90M $48.69M $12.11M
YoY Change 361.06% 301.93% -54.04%
SHAREHOLDERS EQUITY
Retained Earnings -$187.0M -$180.8M -$160.8M
YoY Change 13.13% 12.44% 6.33%
Common Stock $27.00K $27.00K $15.00K
YoY Change 3.85% 80.0% -94.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.233M $3.562M $8.813M
YoY Change
Total Liabilities & Shareholders Equity $49.13M $52.25M $20.93M
YoY Change 120.53% 149.68% -46.88%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$6.161M -$5.600M -$7.300M
YoY Change 36.91% -23.29% -91.52%
Depreciation, Depletion And Amortization $24.00K $20.00K $40.00K
YoY Change 20.0% -50.0% 36.71%
Cash From Operating Activities -$4.658M -$5.830M -$6.110M
YoY Change -14.37% -4.58% -4.87%
INVESTING ACTIVITIES
Capital Expenditures $19.00K $0.00 $50.00K
YoY Change -5.0% -100.0% -828.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$19.00K $0.00 -$50.00K
YoY Change -114.62% -100.0% -99.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.706M 8.540M 10.00K
YoY Change 1.53% 85300.0% -99.71%
NET CHANGE
Cash From Operating Activities -4.658M -5.830M -6.110M
Cash From Investing Activities -19.00K 0.000 -50.00K
Cash From Financing Activities 7.706M 8.540M 10.00K
Net Change In Cash 3.029M 2.710M -6.150M
YoY Change 32.85% -144.07% -76.15%
FREE CASH FLOW
Cash From Operating Activities -$4.658M -$5.830M -$6.110M
Capital Expenditures $19.00K $0.00 $50.00K
Free Cash Flow -$4.677M -$5.830M -$6.160M
YoY Change -14.34% -5.36% -3.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
582-1199
dei Security12b Title
Security12bTitle
Common stock, $0.005 par value per share
dei Trading Symbol
TradingSymbol
ERNA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5410331
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000748592
erna License Agreement Automatic Renewal Term
LicenseAgreementAutomaticRenewalTerm
P2Y6M
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-11460
dei Entity Registrant Name
EntityRegistrantName
Eterna Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-1103425
dei Entity Address Address Line1
EntityAddressAddressLine1
1035 Cambridge Street, Suite 18A
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
59000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5410000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5410000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5127000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5127000
CY2023Q3 us-gaap Revenues
Revenues
51000
CY2022Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
51000
us-gaap Revenues
Revenues
0
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
120000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
0
us-gaap Cost Of Revenue
CostOfRevenue
170000
us-gaap Cost Of Revenue
CostOfRevenue
0
CY2023Q3 us-gaap Gross Profit
GrossProfit
-69000
CY2022Q3 us-gaap Gross Profit
GrossProfit
0
us-gaap Gross Profit
GrossProfit
-119000
us-gaap Gross Profit
GrossProfit
0
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1457000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4963000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4710000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8430000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3979000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3341000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10081000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14060000
CY2023Q3 erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
0
CY2022Q3 erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
0
erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
460000
erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
0
CY2023Q3 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
CY2022Q3 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
5990000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5436000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8304000
us-gaap Operating Expenses
OperatingExpenses
15251000
us-gaap Operating Expenses
OperatingExpenses
28480000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5505000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8304000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15370000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28480000
CY2023Q3 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-20000
CY2022Q3 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-1024000
erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-166000
erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-10493000
CY2023Q3 erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0
CY2022Q3 erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0
erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
118000
erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0
CY2023Q3 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
0
CY2022Q3 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
21000
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
59000
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
932000
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
114000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
10000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
369000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1166000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-94000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
993000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-144000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8395000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5599000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7311000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15514000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20085000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5591000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7316000
us-gaap Net Income Loss
NetIncomeLoss
-15515000
us-gaap Net Income Loss
NetIncomeLoss
-20090000
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
CY2022Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
8000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
8000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5591000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7316000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15523000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20098000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.04
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5410000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5410000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2941000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2941000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5281000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5281000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2855000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2855000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3866000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5113000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
174000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5591000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3562000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12107000
erna Stock Issued During Period Value Acquisitions2
StockIssuedDuringPeriodValueAcquisitions2
208000
erna Stock Issued During Period Value Stock Purchase Agreement
StockIssuedDuringPeriodValueStockPurchaseAgreement
580000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5113000
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
8000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1077000
us-gaap Net Income Loss
NetIncomeLoss
-15515000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3562000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14778000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
331000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1212000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1376000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q3 erna Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
875000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
476000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7316000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8813000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25503000
erna Stock Issued During Period Value Private Offering
StockIssuedDuringPeriodValuePrivateOffering
0
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-5000
erna Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock
StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
0
erna Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
874000
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
8000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2539000
us-gaap Net Income Loss
NetIncomeLoss
-20090000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8813000
us-gaap Net Income Loss
NetIncomeLoss
-15515000
us-gaap Net Income Loss
NetIncomeLoss
-20090000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
62000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144000
us-gaap Share Based Compensation
ShareBasedCompensation
1077000
us-gaap Share Based Compensation
ShareBasedCompensation
2538000
erna Commitment Shares Issue Expense
CommitmentSharesIssueExpense
249000
erna Commitment Shares Issue Expense
CommitmentSharesIssueExpense
0
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-11000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
580000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
267000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
772000
erna Non Cash Research And Development In Process Asset Acquisition
NonCashResearchAndDevelopmentInProcessAssetAcquisition
433000
erna Non Cash Research And Development In Process Asset Acquisition
NonCashResearchAndDevelopmentInProcessAssetAcquisition
0
us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
5990000
erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
1000
erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
431000
erna Gain On Termination Of Lease
GainOnTerminationOfLease
0
erna Gain On Termination Of Lease
GainOnTerminationOfLease
85000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
52000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-166000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10493000
erna Gain Loss On Change In Fair Value Of Contingent Consideration
GainLossOnChangeInFairValueOfContingentConsideration
-118000
erna Gain Loss On Change In Fair Value Of Contingent Consideration
GainLossOnChangeInFairValueOfContingentConsideration
0
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
59000
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
932000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
825000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
237000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-340000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
575000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2911000
erna Issuance Of Common Stock For Asset Acquisition
IssuanceOfCommonStockForAssetAcquisition
0
erna Warrants Issued
WarrantsIssued
5234000
erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
795000
erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-223000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1313000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
3393000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
599000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-369000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
650000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15747000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15541000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
276000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-176000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
8715000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
175000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
erna Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement
320000
erna Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11993000
erna Issuance Of Common Stock From Exercise Of Pre Funded Warrants
IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
0
erna Issuance Of Common Stock From Exercise Of Pre Funded Warrants
IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
7000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
8000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
8000
erna Issuance Of Common Stock From Vested Restricted Stock Units
IssuanceOfCommonStockFromVestedRestrictedStockUnits
0
erna Issuance Of Common Stock From Vested Restricted Stock Units
IssuanceOfCommonStockFromVestedRestrictedStockUnits
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8852000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11986000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6895000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3731000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15541000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16985000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8646000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13254000
us-gaap Interest Paid Net
InterestPaidNet
13000
us-gaap Interest Paid Net
InterestPaidNet
25000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000
erna Contingent Consideration For Asset Acquisition
ContingentConsiderationForAssetAcquisition
225000
erna Contingent Consideration For Asset Acquisition
ContingentConsiderationForAssetAcquisition
0
erna Issuance Of Common Stock For Asset Acquisition
IssuanceOfCommonStockForAssetAcquisition
208000
erna Warrants Issued
WarrantsIssued
0
erna Unpaid Fees Incurred In Connection With The Issuance Of Convertible Notes And Warrants
UnpaidFeesIncurredInConnectionWithTheIssuanceOfConvertibleNotesAndWarrants
27000
erna Unpaid Fees Incurred In Connection With The Issuance Of Convertible Notes And Warrants
UnpaidFeesIncurredInConnectionWithTheIssuanceOfConvertibleNotesAndWarrants
0
erna Initial Measurement Of Right Of Use Assets
InitialMeasurementOfRightOfUseAssets
34410000
erna Initial Measurement Of Right Of Use Assets
InitialMeasurementOfRightOfUseAssets
1706000
erna Initial Measurement Of Lease Liabilities
InitialMeasurementOfLeaseLiabilities
34170000
erna Initial Measurement Of Lease Liabilities
InitialMeasurementOfLeaseLiabilities
1706000
erna Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
0
erna Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
867000
erna Initial Measurement Of Finance Lease Liabilities
InitialMeasurementOfFinanceLeaseLiabilities
0
erna Initial Measurement Of Finance Lease Liabilities
InitialMeasurementOfFinanceLeaseLiabilities
10000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4551000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13254000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
4095000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8646000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13254000
erna Number Of In Licensed Portfolio Patents
NumberOfInLicensedPortfolioPatents
100
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; font-weight: normal; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt; font-style: italic;">Reclassifications</div> <div><br/></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain reclassifications have been made to the Company’s prior year amounts to conform to the current year presentation.<br/> </div>
CY2023Q3 us-gaap Cash
Cash
4600000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180800000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5600000
us-gaap Net Income Loss
NetIncomeLoss
-15500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15700000
CY2022Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
45500
CY2022Q4 us-gaap Line Of Credit
LineOfCredit
4100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
4100000
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
8700000
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6100000
us-gaap Variable Lease Cost
VariableLeaseCost
113000
CY2023Q3 us-gaap Lease Cost
LeaseCost
1608000
CY2023Q2 erna Allocated Percentage Of Fair Value Consideration To Purchased License
AllocatedPercentageOfFairValueConsiderationToPurchasedLicense
1
CY2023Q1 erna Proceeds From Option And License Agreement
ProceedsFromOptionAndLicenseAgreement
300000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
0
CY2023Q3 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
0
CY2023Q3 erna Proceeds From Cell Line Customization Activities
ProceedsFromCellLineCustomizationActivities
400000
erna Option Fee Obligation Payment Percentage
OptionFeeObligationPaymentPercentage
0.20
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
800000
CY2023Q3 erna Lease Liability Incremental Amount Above Tenant Improvement Allowance
LeaseLiabilityIncrementalAmountAboveTenantImprovementAllowance
600000
CY2023Q3 erna Other Receivable For Reimbursement Under Tenant Improvement Allowance
OtherReceivableForReimbursementUnderTenantImprovementAllowance
1100000
CY2023Q3 erna Sublease Tenant Improvement Allowance Paid But Not Submitted For Reimbursement
SubleaseTenantImprovementAllowancePaidButNotSubmittedForReimbursement
3500000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1623000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
143000
us-gaap Operating Lease Cost
OperatingLeaseCost
1758000
us-gaap Operating Lease Cost
OperatingLeaseCost
476000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
21000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
21000
us-gaap Sublease Income
SubleaseIncome
63000
us-gaap Sublease Income
SubleaseIncome
63000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
6000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
60000
us-gaap Variable Lease Cost
VariableLeaseCost
18000
CY2022Q3 us-gaap Lease Cost
LeaseCost
182000
us-gaap Lease Cost
LeaseCost
1713000
us-gaap Lease Cost
LeaseCost
526000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1030000
erna Initial Measurement Of Operating Lease Rou Assets
InitialMeasurementOfOperatingLeaseROUAssets
34410000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
580000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
34860000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1182000
erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
34169000
erna Accretion Of Interest Sublease
AccretionOfInterestSublease
1055000
erna Principal Payments On Operating Lease Liabilities
PrincipalPaymentsOnOperatingLeaseLiabilities
259000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
36147000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34998000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1149000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.126
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
932000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5947000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6065000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6227000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6298000
CY2023Q3 erna Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
40224000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
65693000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
29546000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
36147000
CY2023Q3 erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0
CY2023Q3 us-gaap Goodwill
Goodwill
2000000
CY2023Q2 us-gaap Share Price
SharePrice
2.26
CY2023Q3 us-gaap Share Price
SharePrice
2.18
CY2023Q1 erna Percentage Of Sublicense Fees Paid Before License Expiration Date
PercentageOfSublicenseFeesPaidBeforeLicenseExpirationDate
0.20
CY2023Q1 erna Percentage Of Sublience Fees Received During Renewal Term
PercentageOfSublienceFeesReceivedDuringRenewalTerm
0.30
erna Notice Period For First Termination Of Contract
NoticePeriodForFirstTerminationOfContract
P120D
CY2023Q1 erna Percentage Of Sublience Fees Received During Renewal Term
PercentageOfSublienceFeesReceivedDuringRenewalTerm
0.30
CY2023Q3 erna Percentage Of Sublience Fees Received During Renewal Term
PercentageOfSublienceFeesReceivedDuringRenewalTerm
0.20
CY2023Q3 erna Related Party Transaction Periodic Fees Payment Amount
RelatedPartyTransactionPeriodicFeesPaymentAmount
400000
CY2023Q3 erna Buildout Costs For Facility Current
BuildoutCostsForFacilityCurrent
3249000
CY2022Q4 erna Buildout Costs For Facility Current
BuildoutCostsForFacilityCurrent
0
CY2023Q3 erna Legal Fees And Settlements
LegalFeesAndSettlements
771000
CY2022Q4 erna Legal Fees And Settlements
LegalFeesAndSettlements
1138000
CY2023Q3 erna Accrued Clinical Current
AccruedClinicalCurrent
95000
CY2022Q4 erna Accrued Clinical Current
AccruedClinicalCurrent
570000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
203000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
333000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
121000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1065000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
580000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
520000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5019000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3626000
CY2023Q3 erna Buildout Costs For Facility Current
BuildoutCostsForFacilityCurrent
3200000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
174000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
476000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2538000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
12600000
CY2022Q3 erna Over Subscription Amount Received
OverSubscriptionAmountReceived
600000
CY2022Q3 erna Over Subscription Amount Received
OverSubscriptionAmountReceived
600000
CY2022Q3 erna Transaction Fees Payable
TransactionFeesPayable
1000000
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10807
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14417000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14417000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
722000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
722000

Files In Submission

Name View Source Status
erna-20230930_cal.xml Edgar Link unprocessable
erna-20230930_lab.xml Edgar Link unprocessable
erna-20230930_def.xml Edgar Link unprocessable
0001140361-23-052742-index-headers.html Edgar Link pending
0001140361-23-052742-index.html Edgar Link pending
0001140361-23-052742.txt Edgar Link pending
0001140361-23-052742-xbrl.zip Edgar Link pending
ef20012432_10q.htm Edgar Link pending
ef20012432_10q_htm.xml Edgar Link completed
ef20012432_ex31-1.htm Edgar Link pending
ef20012432_ex31-2.htm Edgar Link pending
ef20012432_ex32-1.htm Edgar Link pending
ef20012432_ex32-2.htm Edgar Link pending
erna-20230930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00007.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
erna-20230930_pre.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending